<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01041677</url>
  </required_header>
  <id_info>
    <org_study_id>CR013735</org_study_id>
    <nct_id>NCT01041677</nct_id>
  </id_info>
  <brief_title>A Study of the Safety of R256918 in Obese Patients</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-Center Study to Evaluate the Effect of JNJ-16269110 on Hepatic Triglyceride Content in Obese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study investigates the safety of 12 weeks of treatment with R256918, in obese patients&#xD;
      (JNJ-16269110 and R256918 are different names for the same molecule). The primary objective&#xD;
      of the study is to investigate mean changes in Hepatic Triglyceride Content (HTGC), which is&#xD;
      the fat content of the liver, from baseline to week 6 and 12 by 1H-Magnetic Resonance&#xD;
      Spectroscopy (MRS), a specialized non invasive radiology test. Additional measures include&#xD;
      body mass index (BMI), fasting glucose,lipid levels, and blood pressure. Safety assessments&#xD;
      performed during the trial include laboratory tests, vital sign measurements, and adverse&#xD;
      event reporting.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized (study drug assigned by chance), double-blind (neither physician nor&#xD;
      patient knows the name of the assigned drug), placebo-controlled , parallel-group study with&#xD;
      3 treatment arms, each consisting of 27 obese patients. The study will include 3 phases -&#xD;
      pretreatment, double-blind and posttreatment . During the pretreatment phase patients undergo&#xD;
      general screening assessments and if eligible, Magnetic Resonance Spectroscopy (MRS)&#xD;
      screening will be performed. During the double-blind treatment phase patients will receive&#xD;
      dietary counseling, study medication, have urine and blood laboratory tests, a follow up MRS&#xD;
      examination and have regular clinic visits for symptoms assessment. The double blind&#xD;
      treatment phase ends with an end-of-treatment or early withdrawal visit. A patient&#xD;
      withdrawing from the study prior to the end of the 12 week treatment phase will attend an&#xD;
      early withdrawal visit, which is the same as the end-of-treatment visit. This visit will&#xD;
      include laboratory tests and a follow up MRS examination. Post-treatment: A follow-up&#xD;
      evaluation will occur 14 days after the end of treatment. Study visits are scheduled to occur&#xD;
      nearly every 14 days following the baseline visit in week 1. The total study duration is&#xD;
      approximately 15 weeks. The study will include the following evaluations of safety and&#xD;
      tolerability: mean percent change in liver fat content at week 6 and week 12 or at the end of&#xD;
      the patients participation in the study, in case of early withdrawal. Safety evaluations for&#xD;
      the study will include the monitoring of adverse events, clinical laboratory tests including&#xD;
      pregnancy testing, electrocardiograms (ECGs), vital sign measurements (pulse and blood&#xD;
      pressure), physical examination, and patient reported assessment of GI symptoms. Special&#xD;
      clinical laboratory safety tests will assess blood clotting or coagulation status, essential&#xD;
      fatty acid status, lipid-soluble vitamin status: vitamin A, vitamin D, vitamin E, vitamin K,&#xD;
      vitamin A/total cholesterol ratio, vitamin E/total cholesterol ratio and liver function&#xD;
      tests. 10 mg capsules, 15 mg capsules, or matching placebo capsules taken orally.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hepatic Triglyceride Content (HTGC) as measured by 1H-Magnetic Resonance Spectroscopy (MRS).</measure>
    <time_frame>Baseline, 6 weeks, 12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Body weight</measure>
    <time_frame>Baseline, weeks 1, 2, 4, 6, 8,10,12,14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in alanine aminotransferase and aspartate aminotransferase</measure>
    <time_frame>Baseline, weeks 4, 6, 8,12,14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in fasting glucose and insulin</measure>
    <time_frame>Baseline, weeks 6, 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in systolic and diastolic blood pressure</measure>
    <time_frame>Baseline, weeks 1, 2, 4, 6, 8, 10, 12, 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in total-, HDL- and LDL-cholesterol and triglycerides</measure>
    <time_frame>Baseline, weeks 6,12</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">71</enrollment>
  <condition>Obesity</condition>
  <condition>Nutritional and Metabolic Diseases</condition>
  <condition>Metabolic Diseases</condition>
  <condition>Nutrition Disorders</condition>
  <condition>Overweight</condition>
  <arm_group>
    <arm_group_label>001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>R256918 10 mg capsule twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>002</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>R256918 15 mg capsule twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>003</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo placebo capsule twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>R256918</intervention_name>
    <description>10 mg capsule twice daily</description>
    <arm_group_label>001</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo capsule twice daily</description>
    <arm_group_label>003</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>R256918</intervention_name>
    <description>15 mg capsule twice daily</description>
    <arm_group_label>002</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Liver fat content (HTGC) between 3% and 15%&#xD;
&#xD;
          -  Obese defined as BMI between 30 and 50 kg/square meter&#xD;
&#xD;
          -  Fasting plasma glucose &lt; 7.0 mmol/liter&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of Obesity with a known cause (eg. Cushings disease)&#xD;
&#xD;
          -  Diabetes Mellitus&#xD;
&#xD;
          -  Weight reducing diet or receiving drugs to treat obesity within 3 months prior to&#xD;
             screening&#xD;
&#xD;
          -  Significant change in smoking habits within 3 months before enrollment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L. C. Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zuidlaren</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>GÃ¶teborg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
    <country>Netherlands</country>
    <country>Sweden</country>
  </location_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_JNJ_6051&amp;studyid=762&amp;filename=CR013735_CSR.pdf</url>
    <description>A Study of the Safety of R256918 in Obese Patients</description>
  </link>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>December 30, 2009</study_first_submitted>
  <study_first_submitted_qc>December 30, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 1, 2010</study_first_posted>
  <disposition_first_submitted>January 19, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>January 19, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">January 21, 2010</disposition_first_posted>
  <last_update_submitted>January 15, 2013</last_update_submitted>
  <last_update_submitted_qc>January 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 24, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Obesity</keyword>
  <keyword>Overweight</keyword>
  <keyword>Body Weight</keyword>
  <keyword>Body Size</keyword>
  <keyword>Nutritional and Metabolic Diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Diseases</mesh_term>
    <mesh_term>Nutrition Disorders</mesh_term>
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

